Clinical Perspectives: Re-Challenging with Immunotherapy
Dr. Daniel George answers when and why patients are re-treated with immunotherapy.
Dr. Daniel George answers when and why patients are re-treated with immunotherapy.
By Dr. Daniel GeorgeChair, KCA Medical Steering CommitteeMedical Oncologist, Duke University There is much more to managing kidney cancer than what guidelines say or what clinical trials can test. That’s why we’ve launched a new…
“When I first got diagnosed, mentally I was fine. After the scan this February, it killed my head. We went from ‘kidney is fine’ to ‘it has to come out’ – that was an emotional swing.”
The following is an excerpt from a blog post by Laura Esfeller, a marketing professional living in California with kidney cancer. Laura writes at singlewhitekidney. I received a letter today that I knew was coming,…
This is a guest post by Nathaniel Stout, who has a stage 4 collecting duct carcinoma diagnosis.
This is a guest post by Kenneth G. Winters, a retired US Navy Chaplain from Massachusetts.
By D’Ann George, PhD, Medical Writer Positive Phase 1 Data on a “new class of drug” for ccRCC There has not been a new class of drugs for people with metastatic renal cell carcinoma (mRCC)…
By D’Ann George, PhD, Medical Writer Racial and ethnic diversity in clinical trials, and the lack of it, was a major theme across research presented at the 2022 meeting of the American Society of Clinical…
Below are some highlights of the research presented at the 2022 meeting of the American Society of Clinical Oncology, which took place in Chicago, Illinois on June 3-7. Much of the kidney cancer data presented…
“Cancer patients are not only more susceptible to the environment around them but also due to the complexities of medical care required.”